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LETTER TO THE EDITOR
Crohn’s disease and intestinal 21  patients  had  TB  latent  infection  and  were  submitted
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Dear  Editor,
The  distinction  between  Crohn’s  disease  and  intesti-
nal  tuberculosis  is  a  diagnostic  challenge  as  they  present
similar  clinical,  radiological,  endoscopic  and  histological
features.1--3 A  deﬁnitive  diagnosis  in  these  cases  is  extremely
important,  to  avoid  the  toxicity  of  unnecessary  anti-
tuberculous  therapy  in  patients  with  Crohn’s  disease  and
potentially  fatal  immunosuppressive  treatment  in  patients
with  intestinal  TB.  Histological  examination,  complemented
by  other  diagnostic  tests,  including  tests  of  nucleic  acid
ampliﬁcation,  is  pivotal  in  the  differential  diagnosis.1,2
Other  methods  like  immunohistochemistry  are  emerging
with  promising  results  in  determining  early  differentiation
of  both  illnesses.3
Patients  with  Crohn’s  disease  eligible  for  TNF  antago-
nist  (inﬂiximab  or  adalimumab)  or  other  immunosuppressive
treatment  are  frequently  sent  to  our  Pneumologic  Diagnosis
Center  for  TB  screening,  as  recommended  by  TBNET  consen-
sus  statement.4 The  screening  program  includes  a  symptom
questionnaire,  a  tuberculin  skin  test  (PPD  RT23),  interferon
gamma  release  assay  (IGRA)  and  chest  radiography.  The
need  for  a  solid  diagnosis,  before  qualifying  patients  for  TNF
antagonists,  led  us  to  include  in  the  screening  programme
a  revision  of  biopsy  specimens  with  acid  fast  bacilli  smear,
nucleic  acid  ampliﬁcation  test  and  cultural  examination  in
recent  biopsies  or,  at  least,  to  ensure  that  these  had  previ-
ously  been  performed.
We  therefore  decided  to  carry  out  a  retrospective  cohort
from  2008  to  analyze  how  this  measure  has  helped  to
exclude  intestinal  tuberculosis  and  safely  qualify  patients
for  anti-TNF  treatment.  We  included  47  patients  with  the
diagnosis  of  Crohn’s  disease;  51%  female  and  mean  age  of
38  years  old.  Revision  of  endoscopic  biopsies  was  possi-
ble  in  25  (53%)  individuals.  Two  (8%)  cases  of  intestinal  TB
were  diagnosed  by  this  process,  one  with  positive  smear,
other  with  both  positive  nucleic  acid  ampliﬁcation  test  and
culture.  Both  started  anti-TB  treatment.  Patients  eligible  for
immunosuppressive  therapy  had  three  different  outcomes:
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doi:10.1016/j.rppneu.2012.02.006o  9-month  isoniazid  regimen;  in  2  patients  Crohn’s  dis-
ase  was  replaced  by  intestinal  TB  as  a  correct  diagnosis;
4  patients  had  negative  TB  screening  and  qualiﬁed  to  for
nti-TNF  treatment.  Twenty-seven  patients  started  anti-TNF
herapy  (the  24  patients  that  had  negative  TB  screening  and
 patients  under  TB  latent  infection  treatment)  and  none
eveloped  active  TB.  In  summary,  this  procedure  allowed
s  to  diagnose  2  cases  of  intestinal  tuberculosis  misin-
erpreted  as  Crohn’s  disease  and  to  safely  initiate  TNF
ntagonist  without  any  case  of  active  TB  following  that
reatment.
In  conclusion,  investigation  of  patients  with  suspected
rohn’s  disease  should  always  include  differential  diag-
osis  with  intestinal  tuberculosis.  Acid  fast  bacilli  smear,
ucleic  acid  ampliﬁcation  tests  and  culture  are  warranted
n  pathological  examination  of  endoscopic  biopsies.  These
rocedures  are  currently  routine  practice  in  our  Pneumo-
ogic  Diagnosis  Center,  when  investigating  patients  with
uspected  Crohn’s  disease.  Alternative  routes  of  differ-
ntiating  both  illnesses  have  been  mentioned  by  others5
nd  may  be  added  to  the  screening  program  in  the
uture.
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